Therapeutic strategies such as TREM2 agonist antibodies, gene delivery, or expression enhancement have been shown to improve Aβ clearance and cognitive outcomes in AD mouse models [142,143,144]. This evidence concerns the gene TREM2 and Alzheimer disease.